Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine


Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

Read More

Next Post

GE Healthcare's Commitment to Cybersecurity

GE Healthcare’s robust cybersecurity risk management system drives a secure enterprise, helps ensure secure products and solutions, delivers secure services and provides a portfolio of cybersecurity managed and consulting services.
Featured Video Play Icon